Back Back
ProCE Banner Activity

CME

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Conference Coverage
Text Module

In this module, Shaji Kumar, MD; Jeffrey Sharman, MD; and Eunice S. Wang, MD, review key studies in hematologic malignancies presented at ASCO 2023.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits™

Released: August 25, 2023

Expiration: August 24, 2024

No longer available for credit.
Begin Activity

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Jeffrey P. Sharman

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis

Target Audience

This program is intended for physicians and other healthcare professionals caring for patients with a hematologic malignancy.

Program Learning Goal

This activity aims to improve learners' understanding of how to optimally apply recent practice-changing findings in treating patients with a hematologic malignancy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with a hematologic malignancy most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with a hematologic malignancy

  • Evaluate new data on novel agents and therapeutic approaches for patients with a hematologic malignancy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor/speaker (paid to institution): AbbVie, Arcellx, BeiGene, Bristol Myers Squibb, Genentech Roche, Janssen, Loxo, K36, Pfizer, Sanofi, Takeda; consultant/advisor/speaker: Antengene, Oncopeptides; research funding (paid to institution): AbbVie, Allogene, Amgen, Bristol Myers Squibb, Carsgen, Genentech Roche, GSK, Regeneron, Takeda. 

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Amgen, Astellas, Bristol Myers Squibb, CTI Biopharma, Daiichi Sankyo, Gilead, GlaxoSmithKline, Janssen, Jazz, Kite, Kura Oncology, Novartis, Pfizer, PharmaEssentia, Rigel, Sellas, Stemline, Sumitomo Pharma.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 25, 2023, through August 24, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.